Related Experiment Videos
[Homocysteine and cardiovascular risk]
L Lutteri1, J P Chapelle, J Gielen
1Service de Chimie médicale, Université de Liège.
Revue Medicale De Liege
|August 14, 1999
Summary
Homocystinuria, a genetic disorder causing high homocysteine (HCY) levels, accelerates atherosclerosis and heart disease. Early detection and treatment with vitamins like folic acid are crucial for managing this cardiovascular risk factor.
Area of Science:
- Biochemistry and Genetics
- Cardiovascular Medicine
Context:
- Homocystinuria is a rare genetic disorder marked by elevated serum homocysteine (HCY).
- Hyperhomocysteinemia is an independent risk factor for cardiovascular disease, even without genetic defects.
Purpose:
- To elucidate the mechanisms by which elevated homocysteine contributes to atherogenesis.
- To highlight the role of B vitamins (folic acid, B12, B6) in managing hyperhomocysteinemia.
- To discuss the evolving diagnostic landscape for homocysteine determination.
Summary:
- Elevated homocysteine promotes atherosclerosis through mechanisms including LDL oxidation, endothelial dysfunction, smooth muscle cell proliferation, and interference with coagulation/fibrinolysis.
- Treatment involves B vitamins, which are cofactors for homocysteine metabolism.
- Homocysteine levels are assessed via basal plasma concentration or methionine loading tests.
- Diagnostic methods are shifting from complex laboratory techniques to widely available automated immunoassays.
Impact:
- Understanding homocysteine's atherogenic potential informs cardiovascular disease risk assessment.
- Highlights the therapeutic importance of B vitamins in managing hyperhomocysteinemia.
- Increased accessibility of homocysteine testing can lead to earlier diagnosis and intervention.